You are viewing: Australia Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Australia Nuclear Medicine Market was valued at $134.9 Million in 2025 and projected to reach to $301.4 Million by 2030, representing a compound annual growth rate of 17.5%. Australia's nuclear medicine market is poised for substantial growth through 2030, driven by increasing healthcare investment and technological advancement in diagnostic and therapeutic applications.

Australia Nuclear Medicine Market Trends and Insights

  • This represents a compound annual growth rate of 17.5%, significantly outpacing global trends.
  • Australia's healthcare infrastructure, coupled with increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures, is driving this accelerated growth trajectory. The Australian nuclear medicine sector is benefiting from rising prevalence of chronic diseases, aging demographics, and enhanced reimbursement frameworks.
  • Australia's investment in advanced medical technologies and skilled nuclear medicine professionals continues to strengthen market fundamentals.
  • Between 2025 and 2030, Australia is expected to consolidate its position as a leading nuclear medicine hub within the Asia Pacific region, supported by regulatory support and clinical innovation. Australia's market growth reflects both increased patient demand and healthcare provider investment in nuclear medicine capabilities.
  • The country's commitment to precision medicine and early disease detection positions Australia favorably for sustained market expansion through 2030..

Key Market Statistics

  • CAGR (2025-2030) 17.5% CAGR
  • Market Size, 2025 ~USD 134.9 Million
  • Forecast, 2030 ~USD 301.4 Million
  • Country Australia

Australia Nuclear Medicine Market Overview

Market Valuation Growth :

Australia's nuclear medicine market is valued at USD 134.9 million in 2025, with projections reaching USD 301.4 million by 2030, demonstrating exceptional market expansion potential.

Superior Growth Rate :

Australia's CAGR of 17.5% significantly outpaces the global nuclear medicine market growth rate of 15.1%, positioning the country as a high-growth market within the Asia-Pacific region.

Advanced Healthcare Infrastructure :

Australia's robust healthcare system and established diagnostic imaging capabilities provide a strong foundation for increased adoption of nuclear medicine procedures across major metropolitan and regional centers.

Expanding Clinical Applications :

Growing utilization of both diagnostic imaging and therapeutic nuclear medicine procedures in oncology, cardiology, and neurology is driving market demand across Australian healthcare facilities.

Australia Nuclear Medicine Market Dynamics

  • The country's aging population and rising prevalence of chronic diseases are accelerating demand for nuclear medicine procedures.
  • Healthcare providers are expanding nuclear medicine capabilities in response to improved reimbursement policies and growing clinical evidence supporting these treatments.
  • Investment in cyclotron facilities and radiopharmaceutical production infrastructure will further strengthen market growth.
  • Australia's regulatory environment and quality healthcare standards continue to attract international players, fostering competitive innovation and service expansion across the sector..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Australia's nuclear medicine market will more than double from USD 134.9M (2025) to USD 301.4M (2030), driven by 17.5% CAGR growth.
    • Australia's aging population and rising chronic disease prevalence are primary catalysts for increased nuclear medicine diagnostic and therapeutic demand.
    • Australia's healthcare system's strong reimbursement policies and regulatory framework support sustained investment in nuclear medicine infrastructure.
    • Australia is positioned as a regional leader in nuclear medicine innovation within Asia Pacific, attracting investment and clinical talent through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    Australia Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Healthcare Facility Operators : Australian hospitals and diagnostic centers require market data to justify capital investments in nuclear medicine equipment, staffing, and facility upgrades based on regional growth projections.
    • Medical Device Manufacturers : Equipment and radiopharmaceutical suppliers need Australia-specific market intelligence to develop localized product strategies, distribution networks, and sales forecasts.
    • Investment and Private Equity Firms : Investors evaluating opportunities in Australian healthcare require detailed market sizing, growth rates, and competitive analysis to assess portfolio companies and acquisition targets.
    • Healthcare Consultants and Advisors : Consulting firms advising Australian healthcare organizations need country-specific market data to support strategic recommendations, feasibility studies, and business case development.
    • Government and Policy Makers : Australian health authorities and policymakers require market insights to inform healthcare infrastructure planning, funding allocation, and regulatory framework development for nuclear medicine services.

    Key Companies in the Australia Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    Reasons to Buy this Report

    • Market Entry Strategy : Comprehensive Australia-specific data enables informed market entry decisions, competitive positioning, and localized business strategy development for nuclear medicine providers and suppliers.
    • Investment Opportunity Assessment : Detailed market valuation and 17.5% CAGR projections provide quantifiable evidence for investment decisions in Australian nuclear medicine infrastructure, facilities, and technology expansion.
    • Competitive Landscape Intelligence : Australia-focused insights reveal market dynamics, key players, and growth drivers specific to the region, enabling competitive differentiation and strategic partnership identification.
    • Regulatory and Reimbursement Insights : Country-specific analysis of Australian healthcare policies, reimbursement frameworks, and regulatory requirements essential for successful market operations and revenue optimization.
    • Growth Forecasting Accuracy : Localized CAGR data and market projections through 2030 support accurate financial modeling, resource allocation, and long-term strategic planning specific to the Australian market.

    Frequently asked questions

    What is the current size of Australia's nuclear medicine market?

    Australia's nuclear medicine market is valued at USD 134.9 million in 2025 and is projected to grow to USD 301.4 million by 2030.

    What is the growth rate of Australia's nuclear medicine market?

    Australia's nuclear medicine market is growing at a compound annual growth rate (CAGR) of 17.5% from 2025 to 2030.

    What factors are driving growth in Australia's nuclear medicine market?

    Key drivers include Australia's aging population, rising prevalence of chronic diseases, strong healthcare infrastructure, favorable reimbursement policies, and increased adoption of precision medicine diagnostics.

    How does Australia's nuclear medicine market compare to global trends?

    Australia's 17.5% CAGR significantly exceeds the global nuclear medicine market CAGR of 15.1%, positioning Australia as a high-growth market within the Asia Pacific region.

    What is the forecast market size for Australia's nuclear medicine sector by 2030?

    Australia's nuclear medicine market is forecast to reach USD 301.4 million by 2030, representing more than a doubling of the 2025 market value.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status